Sleep Aids Safe in Pregnancy
For pregnant patients with insomnia, non-pharmacologic interventions should be prioritized first, but when medication is necessary, melatonin and doxylamine (antihistamine) appear to be the safest options based on available human data, while Z-drugs (particularly zolpidem) show reassuring safety profiles with no meaningful increase in congenital malformations.
Evidence-Based Medication Safety Profile
Safest Options
Melatonin emerges as a reasonable first-line pharmacologic choice when non-pharmacologic measures fail:
- Clinical trials using melatonin during pregnancy have not suggested major safety concerns or adverse events 1
- Contrary to animal studies, human evidence suggests melatonin use during pregnancy and breastfeeding is probably safe 1
- No association with congenital malformations in available studies
Antihistamines (First-Generation H1 Antagonists):
- Examined studies showed no correlation with increased risk of congenital malformations 2
- However, general insomnia guidelines note limited evidence supporting efficacy and have safety concerns 3
Z-Drugs (Zolpidem, Eszopiclone, Zaleplon)
The most robust recent evidence comes from a large 2026 study:
- No meaningful elevation in risk of congenital malformations overall (adjusted pooled RR 1.01,95% CI 0.95-1.08) 4
- Study included over 4.2 million pregnancies with 22,514 first-trimester Z-drug exposures
- 92% of exposures were zolpidem 4
- While small increases were noted for specific rare defects (abdominal wall defects, tetralogy of Fallot, neural tube defects), these were imprecisely estimated and not consistently replicated across cohorts 4
Important caveat: Earlier evidence suggests Z-drugs and benzodiazepines may increase rates of preterm birth, low birthweight, and/or small-for-gestational-age infants 2, though the 2026 study provides more reassuring data on structural malformations specifically.
Benzodiazepines
- No correlation with increased congenital malformations 2
- May increase preterm birth, low birthweight, and small-for-gestational-age infants 2
- Should be considered second-line due to these concerns
Medications with Insufficient Evidence
Antidepressants (sedating types like trazodone, doxepin):
- Examined studies showed no correlation with congenital malformations 2
- However, insufficient evidence exists to determine efficacy specifically for insomnia in pregnancy 3
Clinical Algorithm for Pregnant Patients
First approach: Non-pharmacologic interventions (sleep hygiene, cognitive-behavioral therapy for insomnia)
If medication needed:
- First choice: Melatonin (best safety profile in human pregnancy studies)
- Alternative first choice: Doxylamine (antihistamine with pregnancy data)
- Second choice: Zolpidem (most studied Z-drug, reassuring malformation data but monitor for growth/preterm concerns)
- Avoid: Benzodiazepines unless other options fail (risk of preterm birth, low birthweight)
Shared decision-making: Discuss limited but reassuring human data, potential risks of untreated insomnia on maternal and fetal health
Critical Gaps and Pitfalls
- Major limitation: No randomized controlled trials specifically examining sleep aid efficacy and safety in pregnant populations 1
- Most evidence comes from observational studies and case reports
- Insomnia was not the primary outcome in pregnancy studies of these medications 1
- The small number of studies prohibits definitive interpretation 2
Clinical reality: Despite limited evidence, untreated severe insomnia during pregnancy carries its own risks for maternal and fetal outcomes. When medication is necessary after failed non-pharmacologic approaches, the evidence supports melatonin or carefully selected Z-drugs (particularly zolpidem) as reasonable options with the most reassuring human safety data available 4, 1.